環龍控股(02260.HK)2022年淨利潤5300萬元 同比增長4.6%
格隆匯3月30日丨環龍控股(02260.HK)公吿,儘管2022年疫情給市場帶來了諸多挑戰,得益於集團積極有效的市場策略、穩定的客户渠道及高品質的產品,2022年集團產品銷售、淨利潤實現穩步增長。集團截至2022年12月31日止年度的收益約為人民幣217.8百萬元,同比增加了1.9%,主要原因為產品銷售單價上升所致。
2022年,集團實現淨利潤5,300萬元,同比增長4.6%;集團產品綜合毛利率53.6%,產品產銷率100%;國際業務市場前瞻性佈局逐步顯露成效,2022年國際業務收入同比增長51.5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.